Main Content start here
Main Layout
Report Description

Report Description

Key Insights

Details

Forecast Period

2027-2031

Market Size (2025)

USD 769.23 Million

CAGR (2026-2031)

6.93%

Fastest Growing Segment

Atherosclerosis

Largest Market

North America

Market Size (2031)

USD 1149.88 Million

Market Overview

The Global Point of Care Lipid Test Market is projected to grow from USD 769.23 Million in 2025 to USD 1149.88 Million by 2031 at a 6.93% CAGR. Point of Care (PoC) lipid tests involve the rapid, on-site measurement of lipid profile components such as total cholesterol, HDL, LDL, and triglycerides, without requiring centralized laboratory infrastructure, providing immediate results from small blood samples for swift clinical decisions. The market's expansion is fundamentally driven by the escalating global prevalence of cardiovascular diseases and dyslipidemia, demanding accessible and timely diagnostic solutions. Additionally, increasing health awareness promoting preventive healthcare and significant technological advancements in portable, user-friendly diagnostic devices further propel market growth.

However, a significant challenge impeding market expansion is ensuring the consistent accuracy and reliability of these tests compared to conventional laboratory methods, which can necessitate confirmatory follow-up testing. According to MedTech Europe, in its December 2025 report, total in vitro diagnostic market revenues across the EU27, EFTA, and the United Kingdom reached €13.3 billion in 2023, indicating the broader diagnostic industry's substantial economic footprint.

Key Market Drivers

The rising global burden of cardiovascular diseases (CVDs) and dyslipidemia stands as a critical driver for the Global Point of Care Lipid Test Market. As more individuals worldwide are affected, demand for accessible and timely diagnostic tools grows. PoC lipid tests offer immediate detection and monitoring, vital for managing chronic conditions like dyslipidemia which often precede severe cardiovascular events. This health crisis necessitates solutions deployable outside traditional laboratories, directly supporting patient management. According to the World Health Organization, in May 2026, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. This substantial mortality underscores the urgent need for widespread and efficient screening, positioning PoC lipid tests as an indispensable part of global health strategies.

Further propelling the market is the ongoing decentralization of healthcare services and a shift towards point-of-care settings. This transition enhances patient access to diagnostics and reduces strain on centralized infrastructure. PoC lipid tests are ideally suited, providing rapid results in diverse environments such as clinics, pharmacies, and home care, thereby streamlining workflows and accelerating treatment decisions. According to a PR Newswire report issued on behalf of VentriPoint Diagnostics Ltd., in May 2026, point-of-care diagnostics crossed $58.76 billion globally. This valuation demonstrates expanding adoption and investment in decentralized solutions. Despite this growth, Abbott reported in January 2026 that its total global diagnostics sales for the full year 2025 fell 4.3% to $8.93 billion, reflecting dynamic competitive and economic pressures within the industry.

Download Free Sample Report

Key Market Challenges

A significant factor hindering the growth of the Global Point of Care Lipid Test Market is the consistent assurance of test accuracy and reliability when compared to established conventional laboratory methods. This concern frequently necessitates confirmatory follow-up testing, undermining the immediate utility and convenience that point-of-care solutions are intended to provide. The need for additional verification procedures increases the overall healthcare burden, adding to patient costs and administrative complexities, which can deter widespread adoption of these rapid diagnostic tools.

According to the Association for Diagnostics & Laboratory Medicine, in January 2025, new Clinical Laboratory Improvement Amendments regulatory updates, including those for proficiency testing, saw the College of American Pathologists setting a +/- 6% accuracy threshold for evaluating certain point-of-care test results. Such stringent requirements highlight ongoing industry efforts to address accuracy, simultaneously emphasizing that achieving consistent reliability remains a critical hurdle for market expansion. This persistent gap in perceived or actual performance relative to central laboratory testing directly limits confidence among healthcare providers, thereby restraining the full market potential of PoC lipid tests.

Key Market Trends

The development of connected, multi-analyte point of care diagnostic platforms represents a pivotal trend, shifting beyond basic single-parameter testing towards comprehensive, integrated health assessments. These advanced platforms facilitate real-time data transmission and analysis, enabling seamless integration with electronic health records and remote monitoring systems. This capability enhances clinical decision-making by providing a broader diagnostic picture swiftly and efficiently at the point of care. For instance, Roche committed a $550 million investment in 2025 to expand innovative continuous glucose monitoring access for the global diabetes community, demonstrating the industry's focus on digitally connected and integrated solutions across various health parameters.

Another significant trend is the growing adoption of home-based lipid monitoring and self-care solutions, empowering individuals to actively manage their health conditions outside traditional clinical settings. This shift is driven by increasing patient demand for convenience, privacy, and proactive health management. These solutions, ranging from personal testing devices to digital health apps, enable regular tracking of lipid profiles, which is crucial for managing cardiovascular disease risk factors. The expanding success of self-care diagnostics is evident in company performance; according to Abbott's January 2026 report on their fourth-quarter and full-year 2025 results, sales of continuous glucose monitors grew 12.2% on an organic basis to $2.0 billion for the fourth quarter of 2025, highlighting the robust consumer adoption of at-home health monitoring.

Segmental Insights

The atherosclerosis segment is experiencing the fastest growth within the Global Point of Care Lipid Test Market. This acceleration is primarily driven by the increasing prevalence of risk factors such as hypertension, diabetes, and obesity, which contribute significantly to plaque buildup in arteries and subsequent cardiovascular diseases. Point-of-care lipid tests are crucial for early detection by enabling rapid measurement of lipid levels associated with plaque formation. This facilitates prompt cardiovascular risk assessment and allows healthcare providers to implement timely preventive measures and treatment strategies, further boosting segment expansion.

Regional Insights

North America consistently leads the Global Point of Care Lipid Test Market, primarily due to its highly developed healthcare infrastructure and significant public awareness regarding cardiovascular diseases. The region benefits from substantial investments in advanced diagnostic technologies and a strong focus on preventive healthcare initiatives, which encourage widespread adoption of point-of-care testing solutions. Favorable reimbursement policies and robust regulatory support from bodies such as the U.S. Food and Drug Administration (FDA) further solidify North America's dominant position. These factors collectively contribute to the region's prominent market share and sustained leadership in the global landscape.

Recent Developments

  • In April 2026, Avricore Health Inc. announced key advancements and its strategic expansion roadmap for the HealthTab™ point-of-care testing platform in the United Kingdom. Through a collaboration with Barts Health NHS Trust, the platform successfully screened over 3,500 patients in community pharmacies across North East and North Central London. An initial lipid-screening group of 556 patients demonstrated that approximately one in five exhibited elevated cardiovascular risk. This highlights HealthTab™'s efficacy in facilitating point-of-care lipid testing and supports the company's efforts to scale its platform within the NHS.
  • In November 2025, breakthrough research was presented at the American Heart Association's Scientific Sessions, indicating that a combined analysis of three cardiovascular disease biomarkers could enable earlier identification of high-risk individuals. The study revealed that adults with elevated levels of lipoprotein a (Lp(a)), remnant cholesterol, and high-sensitivity C-reactive protein (hsCRP) faced nearly triple the risk of a heart attack compared to those with normal levels. This research underscores the potential for developing more personalized prevention strategies based on evaluating these integrated blood test results, which could significantly influence the development of future point-of-care lipid testing panels.
  • In October 2025, goodscare's gc diagnostics business unit was recognized with the Health-i Award 2025 for its innovative Igloo rapid diagnostic device. Developed in partnership with Dx365, Igloo represents a new generation of digital point-of-care diagnostic technology, capable of providing laboratory-quality results from various rapid medical tests within minutes. The device is designed for versatile use in diverse healthcare settings, including pharmacies and medical practices, thereby enhancing access to high-quality diagnostics. Its capability to analyze a substantial majority of commercially available rapid tests positions it to contribute to lipid test market advancements.
  • In July 2025, the "Lipids Optimisation Point of Care Testing (POCT)" project, a component of the Health Innovation Accelerator, actively deployed cholesterol testing in community settings across Greater Manchester. This collaborative initiative involved co-investment from companies such as Novartis and Innovate UK, working alongside local healthcare entities. The project's objective was to address health inequalities related to cardiovascular risk by providing instant POCT results that were directly integrated with primary care for necessary action. Initial findings from over 360 tests highlighted that a significant portion of individuals had elevated cholesterol levels that may have otherwise gone undetected.

Key Market Players

  • Callegari Srl
  • Sinocare Inc.
  • Abbott Laboratories
  • MiCoBio
  • Nova Biomedical
  • VivaChek Biotech Hangzhou Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Menarini Group
  • SD Biosensor Inc.
  • Becton Dickinson and Company

By Product

By Application

By Disease Indication

By End User

By Region

  • Instruments
  • Consumables
  • Hyperlipidemia
  • Hypertriglyceridemia
  • Tangier Disease
  • Hyperlipoproteinemia
  • Familial Hypercholesterolemia
  • Others
  • Lipid and Lipoprotein Disorders
  • Atherosclerosis
  • Liver and Renal Diseases
  • Diabetes Mellitus
  • Others
  • Hospitals
  • Clinics
  • Research and Diagnostic Laboratories
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Point of Care Lipid Test Market , By Product:
  • Instruments
  • Consumables
  • Point of Care Lipid Test Market , By Application:
  • Hyperlipidemia
  • Hypertriglyceridemia
  • Tangier Disease
  • Hyperlipoproteinemia
  • Familial Hypercholesterolemia
  • Others
  • Point of Care Lipid Test Market , By Disease Indication:
  • Lipid and Lipoprotein Disorders
  • Atherosclerosis
  • Liver and Renal Diseases
  • Diabetes Mellitus
  • Others
  • Point of Care Lipid Test Market , By End User:
  • Hospitals
  • Clinics
  • Research and Diagnostic Laboratories
  • Others
  • Point of Care Lipid Test Market , By Region:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market .

Available Customizations:

Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Point of Care Lipid Test Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Point of Care Lipid Test Market Outlook

5.1.  Market Size & Forecast

5.1.1.  By Value

5.2.  Market Share & Forecast

5.2.1.  By Product (Instruments, Consumables)

5.2.2.  By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)

5.2.3.  By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)

5.2.4.  By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)

5.2.5.  By Region

5.2.6.  By Company (2025)

5.3.  Market Map

6.    North America Point of Care Lipid Test Market Outlook

6.1.  Market Size & Forecast

6.1.1.  By Value

6.2.  Market Share & Forecast

6.2.1.  By Product

6.2.2.  By Application

6.2.3.  By Disease Indication

6.2.4.  By End User

6.2.5.  By Country

6.3.    North America: Country Analysis

6.3.1.    United States Point of Care Lipid Test Market Outlook

6.3.1.1.  Market Size & Forecast

6.3.1.1.1.  By Value

6.3.1.2.  Market Share & Forecast

6.3.1.2.1.  By Product

6.3.1.2.2.  By Application

6.3.1.2.3.  By Disease Indication

6.3.1.2.4.  By End User

6.3.2.    Canada Point of Care Lipid Test Market Outlook

6.3.2.1.  Market Size & Forecast

6.3.2.1.1.  By Value

6.3.2.2.  Market Share & Forecast

6.3.2.2.1.  By Product

6.3.2.2.2.  By Application

6.3.2.2.3.  By Disease Indication

6.3.2.2.4.  By End User

6.3.3.    Mexico Point of Care Lipid Test Market Outlook

6.3.3.1.  Market Size & Forecast

6.3.3.1.1.  By Value

6.3.3.2.  Market Share & Forecast

6.3.3.2.1.  By Product

6.3.3.2.2.  By Application

6.3.3.2.3.  By Disease Indication

6.3.3.2.4.  By End User

7.    Europe Point of Care Lipid Test Market Outlook

7.1.  Market Size & Forecast

7.1.1.  By Value

7.2.  Market Share & Forecast

7.2.1.  By Product

7.2.2.  By Application

7.2.3.  By Disease Indication

7.2.4.  By End User

7.2.5.  By Country

7.3.    Europe: Country Analysis

7.3.1.    Germany Point of Care Lipid Test Market Outlook

7.3.1.1.  Market Size & Forecast

7.3.1.1.1.  By Value

7.3.1.2.  Market Share & Forecast

7.3.1.2.1.  By Product

7.3.1.2.2.  By Application

7.3.1.2.3.  By Disease Indication

7.3.1.2.4.  By End User

7.3.2.    France Point of Care Lipid Test Market Outlook

7.3.2.1.  Market Size & Forecast

7.3.2.1.1.  By Value

7.3.2.2.  Market Share & Forecast

7.3.2.2.1.  By Product

7.3.2.2.2.  By Application

7.3.2.2.3.  By Disease Indication

7.3.2.2.4.  By End User

7.3.3.    United Kingdom Point of Care Lipid Test Market Outlook

7.3.3.1.  Market Size & Forecast

7.3.3.1.1.  By Value

7.3.3.2.  Market Share & Forecast

7.3.3.2.1.  By Product

7.3.3.2.2.  By Application

7.3.3.2.3.  By Disease Indication

7.3.3.2.4.  By End User

7.3.4.    Italy Point of Care Lipid Test Market Outlook

7.3.4.1.  Market Size & Forecast

7.3.4.1.1.  By Value

7.3.4.2.  Market Share & Forecast

7.3.4.2.1.  By Product

7.3.4.2.2.  By Application

7.3.4.2.3.  By Disease Indication

7.3.4.2.4.  By End User

7.3.5.    Spain Point of Care Lipid Test Market Outlook

7.3.5.1.  Market Size & Forecast

7.3.5.1.1.  By Value

7.3.5.2.  Market Share & Forecast

7.3.5.2.1.  By Product

7.3.5.2.2.  By Application

7.3.5.2.3.  By Disease Indication

7.3.5.2.4.  By End User

8.    Asia Pacific Point of Care Lipid Test Market Outlook

8.1.  Market Size & Forecast

8.1.1.  By Value

8.2.  Market Share & Forecast

8.2.1.  By Product

8.2.2.  By Application

8.2.3.  By Disease Indication

8.2.4.  By End User

8.2.5.  By Country

8.3.    Asia Pacific: Country Analysis

8.3.1.    China Point of Care Lipid Test Market Outlook

8.3.1.1.  Market Size & Forecast

8.3.1.1.1.  By Value

8.3.1.2.  Market Share & Forecast

8.3.1.2.1.  By Product

8.3.1.2.2.  By Application

8.3.1.2.3.  By Disease Indication

8.3.1.2.4.  By End User

8.3.2.    India Point of Care Lipid Test Market Outlook

8.3.2.1.  Market Size & Forecast

8.3.2.1.1.  By Value

8.3.2.2.  Market Share & Forecast

8.3.2.2.1.  By Product

8.3.2.2.2.  By Application

8.3.2.2.3.  By Disease Indication

8.3.2.2.4.  By End User

8.3.3.    Japan Point of Care Lipid Test Market Outlook

8.3.3.1.  Market Size & Forecast

8.3.3.1.1.  By Value

8.3.3.2.  Market Share & Forecast

8.3.3.2.1.  By Product

8.3.3.2.2.  By Application

8.3.3.2.3.  By Disease Indication

8.3.3.2.4.  By End User

8.3.4.    South Korea Point of Care Lipid Test Market Outlook

8.3.4.1.  Market Size & Forecast

8.3.4.1.1.  By Value

8.3.4.2.  Market Share & Forecast

8.3.4.2.1.  By Product

8.3.4.2.2.  By Application

8.3.4.2.3.  By Disease Indication

8.3.4.2.4.  By End User

8.3.5.    Australia Point of Care Lipid Test Market Outlook

8.3.5.1.  Market Size & Forecast

8.3.5.1.1.  By Value

8.3.5.2.  Market Share & Forecast

8.3.5.2.1.  By Product

8.3.5.2.2.  By Application

8.3.5.2.3.  By Disease Indication

8.3.5.2.4.  By End User

9.    Middle East & Africa Point of Care Lipid Test Market Outlook

9.1.  Market Size & Forecast

9.1.1.  By Value

9.2.  Market Share & Forecast

9.2.1.  By Product

9.2.2.  By Application

9.2.3.  By Disease Indication

9.2.4.  By End User

9.2.5.  By Country

9.3.    Middle East & Africa: Country Analysis

9.3.1.    Saudi Arabia Point of Care Lipid Test Market Outlook

9.3.1.1.  Market Size & Forecast

9.3.1.1.1.  By Value

9.3.1.2.  Market Share & Forecast

9.3.1.2.1.  By Product

9.3.1.2.2.  By Application

9.3.1.2.3.  By Disease Indication

9.3.1.2.4.  By End User

9.3.2.    UAE Point of Care Lipid Test Market Outlook

9.3.2.1.  Market Size & Forecast

9.3.2.1.1.  By Value

9.3.2.2.  Market Share & Forecast

9.3.2.2.1.  By Product

9.3.2.2.2.  By Application

9.3.2.2.3.  By Disease Indication

9.3.2.2.4.  By End User

9.3.3.    South Africa Point of Care Lipid Test Market Outlook

9.3.3.1.  Market Size & Forecast

9.3.3.1.1.  By Value

9.3.3.2.  Market Share & Forecast

9.3.3.2.1.  By Product

9.3.3.2.2.  By Application

9.3.3.2.3.  By Disease Indication

9.3.3.2.4.  By End User

10.    South America Point of Care Lipid Test Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value

10.2.  Market Share & Forecast

10.2.1.  By Product

10.2.2.  By Application

10.2.3.  By Disease Indication

10.2.4.  By End User

10.2.5.  By Country

10.3.    South America: Country Analysis

10.3.1.    Brazil Point of Care Lipid Test Market Outlook

10.3.1.1.  Market Size & Forecast

10.3.1.1.1.  By Value

10.3.1.2.  Market Share & Forecast

10.3.1.2.1.  By Product

10.3.1.2.2.  By Application

10.3.1.2.3.  By Disease Indication

10.3.1.2.4.  By End User

10.3.2.    Colombia Point of Care Lipid Test Market Outlook

10.3.2.1.  Market Size & Forecast

10.3.2.1.1.  By Value

10.3.2.2.  Market Share & Forecast

10.3.2.2.1.  By Product

10.3.2.2.2.  By Application

10.3.2.2.3.  By Disease Indication

10.3.2.2.4.  By End User

10.3.3.    Argentina Point of Care Lipid Test Market Outlook

10.3.3.1.  Market Size & Forecast

10.3.3.1.1.  By Value

10.3.3.2.  Market Share & Forecast

10.3.3.2.1.  By Product

10.3.3.2.2.  By Application

10.3.3.2.3.  By Disease Indication

10.3.3.2.4.  By End User

11.    Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.    Market Trends & Developments

12.1.  Merger & Acquisition (If Any)

12.2.  Product Launches (If Any)

12.3.  Recent Developments

13.    Global Point of Care Lipid Test Market : SWOT Analysis

14.    Porter's Five Forces Analysis

14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Products

15.    Competitive Landscape

15.1.  Callegari Srl

15.1.1.  Business Overview

15.1.2.  Products & Services

15.1.3.  Recent Developments

15.1.4.  Key Personnel

15.1.5.  SWOT Analysis

15.2.  Sinocare Inc.

15.3.  Abbott Laboratories

15.4.  MiCoBio

15.5.  Nova Biomedical

15.6.  VivaChek Biotech Hangzhou Co. Ltd.

15.7.  F. Hoffmann-La Roche Ltd.

15.8.  Menarini Group

15.9.  SD Biosensor Inc.

15.10.  Becton Dickinson and Company

16.    Strategic Recommendations

17.    About Us & Disclaimer

Figures and Tables

Frequently asked questions

Frequently asked questions

The market size of the Global Point of Care Lipid Test Market was estimated to be USD 769.23 Million in 2025.

North America is the dominating region in the Global Point of Care Lipid Test Market .

Atherosclerosis segment is the fastest growing segment in the Global Point of Care Lipid Test Market .

The Global Point of Care Lipid Test Market is expected to grow at 6.93% between 2026 to 2031.

Related Reports

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.